SCHEDULE Follow Up Visit 5-7 yr
- Status
- COMPLETED
- Phase
- PHASE4
Clinical Trials Related to Everolimus
Related studies linked through entity extraction aliases.
Topical Everolimus in Patients With Tuberous Sclerosis Complex
- Status
- WITHDRAWN
- Phase
- PHASE2/PHASE3
Phase IV Study of the Safety and Efficacy of Everolimus in Adult Patients With Progressive pNET in China
- Status
- COMPLETED
- Phase
- PHASE4
Molecularly Target Therapy With GEMOX in Advanced or Recurrent Extrahepatic Cholangiocarcinoma and Gallbladder Carcinoma
- Status
- UNKNOWN
- Phase
- PHASE2
European Proof-of-Concept Therapeutic Stratification Trial of Molecular Anomalies in Relapsed or Refractory Tumors
- Status
- RECRUITING
- Phase
- PHASE1/PHASE2
Single-centre Study of Everolimus as GvHD Prophylaxis After Post-Transplantation Cyclophosphamide After Allogeneic SCT
- Status
- COMPLETED
- Phase
- PHASE2
Lenvatinib/Everolimus or Lenvatinib/Pembrolizumab Versus Sunitinib Alone as Treatment of Advanced Renal Cell Carcinoma
- Status
- ACTIVE_NOT_RECRUITING
- Phase
- PHASE3
Dried Blood SPOT Analysis of Everolimus in Cancer Patients (SPOT-study)
- Status
- COMPLETED
- Phase
- N/A
A Trial of Neoadjuvant Everolimus Plus Letrozole Versus FEC in Women With ER-positive, HER2-negative Breast Cancer
- Status
- COMPLETED
- Phase
- PHASE2
Study of Ribociclib With Everolimus + Exemestane in HR+ HER2- Locally Advanced/Metastatic Breast Cancer Post Progression on CDK 4/6 Inhibitor.
- Status
- COMPLETED
- Phase
- PHASE1/PHASE2
MLN0128 and MLN0128 + MLN1117 Compared With Everolimus in the Treatment of Adults With Advanced or Metastatic Clear-Cell Renal Cell Carcinoma
- Status
- COMPLETED
- Phase
- PHASE2
Treg Therapy in Subclinical Inflammation in Kidney Transplantation
- Status
- COMPLETED
- Phase
- PHASE1/PHASE2
Study of Everolimus as Maintenance Therapy for Metastatic NEC With Pulmonary or Gastroenteropancreatic Origin
- Status
- UNKNOWN
- Phase
- PHASE2
Genomics-Based Target Therapy for Children With Relapsed or Refractory Malignancy
- Status
- UNKNOWN
- Phase
- PHASE2
Safety and Tolerability of Everolimus in Combination With Eribulin in Triple-negative Breast Cancers
- Status
- UNKNOWN
- Phase
- PHASE1
Study to Evaluate Ibrutinib Combination Therapy in Patients With Selected Gastrointestinal and Genitourinary Tumors
- Status
- COMPLETED
- Phase
- PHASE1/PHASE2
Study of the Combination of CM082 With Everolimus in Patients With mRCC
- Status
- UNKNOWN
- Phase
- PHASE1
Open Label Study of Everolimus (RAD001) in Patients With Segmental Overgrowth Syndrome
- Status
- WITHDRAWN
- Phase
- PHASE2
Personalized Targeted Inhibitors Treatment in Renal Cell Cancer
- Status
- TERMINATED
- Phase
- PHASE2
Sporadic Angiomyolipomas (AMLs) Growth Kinetics While on Everolimus
- Status
- TERMINATED
- Phase
- PHASE2